De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections

Journal of Medical Economics

Volumn 16, Issue 11, 2013, Pages 1344-1356

  Masterton, Robert G ^a   Casamayor, Montserrat ^b   Musingarimi, Primrose ^c   Van Engen, Anke ^b   Zinck, Raymund ^d   Odufowora Sita, Olatunji ^c   Odeyemi, Isaac A O ^c  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b IQVIA   (United States)

^c Astellas Pharma UK Ltd   (United Kingdom)

^d Astellas Pharma Global Development   (Netherlands)

Author keywords

Echinocandins; Fluconazole; Micafungin; Systemic Candida infections

Indexed keywords

FLUCONAZOLE; MICAFUNGIN;

ARTICLE; CANDIDIASIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FUNGUS ISOLATION; HEALTH CARE COST; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; QUALITY ADJUSTED LIFE YEAR;

ANTIFUNGAL AGENTS; CANDIDIASIS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ECHINOCANDINS; FLUCONAZOLE; HEALTH SERVICES; HUMANS; LIFE EXPECTANCY; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84886413791     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.839948     Document Type: Article

References (64)

1. Hassan I, Powell G, Sidhu M, et al. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009;59:360-5
2. HPA. Candidaemia in England, Wales and Northern Ireland: 2009. Health Protection Report [serial online] 2008 [date cited]; 4(37): HCAI. Available at: http://www.hpa.org.uk/Publications/HealthProtection/HealthProtection Report/HealthProtectionReportHPR/. Accessed 2 Feb 2011
3. Odds FC, Hanson MF, Davidson AD, et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007;56: 1066-75
4. Karabinis A, Hill C, Leclercq B, et al. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429-32
5. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009;13:R94. doi: 10.1186/cc7924. Epub 2009 Jun 19
6. Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150
7. Ullmann AJ, Comely OA, Donnelly JP, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012;18:1-8
8. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
9. Prentice AG, Glasmacher A, Hobson RP, et al. Guidelines on the management of invasive fungal infection during therapy for haemato-logical malignancy. British Committee for Standards in Haematology 2008. Available at: http://www.bcshguidelines.com/documents/fungal-infection-bcsh-2008.pdf
10. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003;123:500-3
11. Nguyen MH, Peacock Jr JE, Morris AJ, et al. The changing face of candide-mia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23
12. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63
13. Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309-21
14. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008;52:3022-8
15. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003;63:2157-68
16. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410
17. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-45
18. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30
19. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72
20. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidaemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31
21. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136:1237-48
22. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5
23. Labelle AJ, Micek ST, Roubinian N, et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008;36:2967-2
24. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55
25. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82
26. Kale-Pradhan PB, Morgan G, Wilhelm SM, et al. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsi-losis Infections: a meta-analysis. Pharmacotherapy 2010;30:1207-13
27. Chalmers CM, Bal AM. Management of fungal infections in the intensive care unit: a survey of UK practice. Br J Anaesth 2011; 106:827-31
28. Review of time needed for Candida identification and susceptibility test in several hospitals in the UK. Unpublished research conducted by the authors. In-house data.
29. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006;19:435-47
30. Summary of product characteristics for Mycamine. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-lnfor mation/human/000734/WC500031075.pdf. Accessed 5 Dec 2010.
31. British National Formulary 59. British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2010. Available at: http://www.bnf.org/bnf/index.htm
32. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidaemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
33. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27
34. Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010;32:637-48
35. Horn DL, Ostrosky-Zeichner L, Morris Ml, et al. Factors related to survival and treatment success in invasive candidiasis or candidaemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 2010;29:223-9
36. Slavin MA, Sorrell TC, Marriott D, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010;65:1042-51
37. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009;115:4745-52
38. Marfo K, Guo Y. Pharmacoeconomic analysis of Micafungin (Mycamine) 100 mg and 150mg daily in the treatment of candidemia. Pharm Ther 2009;34:196-9.
39. HPA Candidaemia in England, Wales and Northern Ireland: 2007. Health Protection Report [serial online] 2009 [date cited]; 3(37): HCAI. Available at: http://www.hpa.org.uk/Publications/HealthProtection/HealthProtection Report/HealthProtectionReportHPR/. Accessed 2 Feb 2011
40. Unpublished data, personal communication with the HPA
41. Weighted average of codes XC01Z, XC02Z, XC03Z, XC04Z, XC05Z, XC06Z and XC07Z, 0 to 6 organs supported. NHS Trusts Critical Care Services-Adult: Critical Care Unit. NHS costs 2008-2009. Available at: http://webarch-ive. nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-111591
42. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-8
43. Cuthbertson BH, Roughton S, Jenkinson D, et al. Quality of life in the five years after intensive care: a cohort study. Crit Care 2010;14:R6. doi: 10.1186/cc8848. Epub2010Jan20
44. Fowler RA, Garber AM, Hill-Popper M, et al. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003;18:181-91; discussion 191-4
45. Eldar-Lissai A, Cosier LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172-9
46. Tunis S, Baran R, Charles M. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. Curr Med Res Opin 2008;24:3085-96.
47. Yun HR, Bae S-C, Yun HR. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol Int 2005;25:9-14
48. Morris S, Cox B, Bosanquet N. Cost of skin cancer in England. Eur J Health Econ 2009;10:267-73
49. Fourcade RO, Benedict A, Black LK, et al. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int 2010;105:49-56
50. Lacau St Guily J, Borget I, Vainchtock A, et al. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol 2010;2:22. doi: 10.1186/1758-3284-2-22
51. Thomas RJ, Williams M, Marshall C, et al. The total hospital and community UK costs of managing patients with relapsed breast cancer. Br J Cancer 2009;100:598-600
52. Clarke PM, Gray AM, Briggs A, et al. UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
53. Nolan JJ, O'Halloran D, McKenna TJ, et al. The cost of treating type 2 diabetes (CODEIRE). Ir Med J 2006;99:307-10
54. Walters S, Rachet B, Westlake S, et al. Cancer survival, England, patients diagnosed 2001-2006 and followed up to 2007: one-year and five-year survival for 21 common cancers, by sex and age. Available at: http://www.ons. gov.uk/ons/search/index. html?newquery=cancer+survival%2C+ england%2C+patients+diagnosed+2001-2006. Accessed 1 Oct 2010
55. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncoglogist 2005;10(3 Suppl):20-9
56. Mulcahy N. New chemotherapy improves survival in metastatic prostate cancer 2010 Genitourinary Cancers Symposium (GUCS), Abstract 9. San Francisco, CA. Available at: http://www.medscape.com/viewarticle/717928. Accessed 1 Oct 2010.
57. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-9
58. Sher DJ. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol 2009;21:1072-7
59. NHS NICE. Guide to the methods of technology appraisal. 2008. National Institute for Health and Clinical Excellence. Available at: http://www.nice. org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 5 Oct 2010
60. Cost-acceptability curve, data on-file.
61. Prowle JR, Echeverri JE, Ligabo EV, et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 2011;15:R100. doi: 10.1186/cc10114. Epub 2011 Mar 21
62. Schelenz S, Barnes RA, Kibbler CC, et al. Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect 2009;58:145-53
63. Electronic Medicines Compendium. Available at: http://www.medi-cines.org. uk/emc/medicine/20997/SPC/Mycamine+50mg+and+100mg+ powder+for+solution+for+infusion/. Accessed 1 Oct 2010
64. Axner-Elings M, Botero-Kleiven S, Jensen RH, et al. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J Clin Microbiol 2011;49:2516-21